[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fWW-w2W0mJGC8IxFbcDg6dkKYzCWXKVZO6k6eY9a_Dlc":8,"$fT0S6p-5l6zMx4TYOzBVbzcVh5DPlajIcIL8_M17uJTA":54,"$fDvsPWOammlEpLUDfkKJFuJEtBKgHMvAtXUfZYE5opOU":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":53},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":6,"materialTotal":19,"videoTotal":20,"isConcern":7,"title":21,"coverVertical":17,"coverAcross":22,"content":23,"description":24,"views":25,"likes":20,"isThumbsUp":7,"isCollection":7,"collections":20,"createTime":26,"seoTitle":27,"seoKeywords":28,"seoDescription":29,"shelvesTime":30,"version":31,"menus":32,"menuId":34,"type":41,"quality":52,"commentCount":20,"isComment":6},54479,869855,[],"https://cdn.yishi-tong.com/console/store-15/BP6b15iseZc2K8zaxYK73fu684DKtpFp.png","病理侦探社","","病理科",213,0,"乳腺导管原位癌的全面解析：病理分级与治疗选择","https://ystcdn.venuertc.com/venue/AI/a2f52520-d738-4231-a7ac-2102ac6dee25.jpg","\u003Cdiv class=\"material-breast-cancer-wrapper\">   \u003Ch1 id=\"material_title\" class=\"material-breast-cancer-title\">     揭开乳腺导管原位癌的神秘面纱：病理分级的全面解析   \u003C/h1>      \u003C!-- 01 乳腺导管原位癌概述 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg1\">     \u003Ch2 class=\"material-breast-cancer-h2\">       01 乳腺导管原位癌是什么？日常中你察觉不到的小变化     \u003C/h2>     \u003Cdiv class=\"material-breast-cancer-content\">       \u003Cp>         忙碌的早晨照镜子，有时候你会发现乳房皮肤下有些许小硬块，摸起来像一粒米，有点像衣服粘到皮肤的感觉，但不疼，也不会影响日常生活。乳腺导管原位癌（Ductal Carcinoma In Situ, \u003Cb>DCIS\u003C/b>）正是这样一种变化：它的细胞虽然异常，却还停留在导管内部，没有扩散出去。\u003Cbr/>         实际上，DCIS 只占乳腺癌新发病例的15%~20%，但近年来体检筛查普及，发现率也逐年上升。根据\u003Cspan class=\"material-breast-cancer-data\">美国癌症协会\u003C/span>数据，女性一生中被诊断为DCIS的风险约为1/20。到目前为止，它还属于“早期癌”，远未发展到威胁生命的程度。       \u003C/p>       \u003Cdiv class=\"material-breast-cancer-tip material-breast-cancer-tip1\">         \u003Cspan>小贴士🧐\u003C/span>         \u003Cul>           \u003Cli>乳腺导管原位癌大多在体检时被发现，没有典型不适\u003C/li>           \u003Cli>它不同于浸润性乳腺癌，不会马上威胁生命，但值得重视\u003C/li>         \u003C/ul>       \u003C/div>     \u003C/div>   \u003C/section>      \u003C!-- 02 病理分级的意义 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg2\">     \u003Ch2 class=\"material-breast-cancer-h2\">       02 病理分级——评估病情的关键尺度     \u003C/h2>     \u003Cdiv class=\"material-breast-cancer-content\">       \u003Cp>         体检报告里经常会看到“低分级”或“高分级”这样的字眼，很多人都搞不懂是什么意思。其实，病理分级就像给肿瘤“打分”，比如学生的考卷分三档，反映了细胞变化的剧烈程度。       \u003C/p>       \u003Cp>         \u003Cb>低分级\u003C/b>的DCIS细胞变化轻微，排布还算整齐，相对比较温和；\u003Cb>高分级\u003C/b>就像“调皮学生”，细胞异常分裂，甚至能看到坏死灶，未来向恶化发展的风险更高。这样一分档，医生就能用不同的“对策”制定后续治疗。\u003Cbr/>         \u003Cspan class=\"material-breast-cancer-highlight\">分级直接影响治疗方式和复发概率，非常值得关注。\u003C/span>       \u003C/p>       \u003Cdiv class=\"material-breast-cancer-table-container\">         \u003Ctable class=\"material-breast-cancer-table\" cellspacing=\"0\">           \u003Cthead>             \u003Ctr>               \u003Cth>分级\u003C/th>               \u003Cth>细胞形态变化\u003C/th>               \u003Cth>临床意义\u003C/th>             \u003C/tr>           \u003C/thead>           \u003Ctbody>             \u003Ctr>               \u003Ctd>低分级\u003C/td>               \u003Ctd>分裂慢，排列整齐\u003C/td>               \u003Ctd>复发风险较低，治疗相对保守\u003C/td>             \u003C/tr>             \u003Ctr>               \u003Ctd>中分级\u003C/td>               \u003Ctd>部分不规则，有轻度坏死\u003C/td>               \u003Ctd>风险适中，根据综合评估决策\u003C/td>             \u003C/tr>             \u003Ctr>               \u003Ctd>高分级\u003C/td>               \u003Ctd>分裂活跃，坏死明显\u003C/td>               \u003Ctd>预后偏差，治疗需积极干预\u003C/td>             \u003C/tr>           \u003C/tbody>         \u003C/table>       \u003C/div>       \u003Cdiv class=\"material-breast-cancer-tip material-breast-cancer-tip2\">         \u003Cspan>友情提醒🔍\u003C/span>         \u003Cul>           \u003Cli>病理分级报告一定要保留好，后续治疗离不开它\u003C/li>           \u003Cli>分级不同，复查及监测计划也不一样\u003C/li>         \u003C/ul>       \u003C/div>     \u003C/div>   \u003C/section>      \u003C!-- 03 乳腺导管原位癌的病理分级标准 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg3\">     \u003Ch2 class=\"material-breast-cancer-h2\">       03 各家标准怎么分？LCIS和DCIS的不同     \u003C/h2>     \u003Cdiv class=\"material-breast-cancer-content\">       \u003Cp>         乳腺导管原位癌主要分为两类：一种是常说的DCIS（导管原位癌），另一种叫 \u003Cb>LCIS\u003C/b>（小叶原位癌）。临床上，真正“做恶”的多为DCIS。两者的分级标准虽各有不同，但判断依据都离不开显微镜下——细胞的形态、排列以及有无坏死。       \u003C/p>       \u003Cdiv class=\"material-breast-cancer-table-container\">         \u003Ctable class=\"material-breast-cancer-table2\" cellspacing=\"0\">           \u003Cthead>             \u003Ctr>               \u003Cth>类型\u003C/th>               \u003Cth>主要特征\u003C/th>               \u003Cth>分级系统\u003C/th>               \u003Cth>临床决策\u003C/th>             \u003C/tr>           \u003C/thead>           \u003Ctbody>             \u003Ctr>               \u003Ctd>DCIS\u003C/td>               \u003Ctd>导管内细胞异型，排列异常\u003C/td>               \u003Ctd>低-中-高分级（三档制）\u003C/td>               \u003Ctd>分级越高，手术/放疗可能性越大\u003C/td>             \u003C/tr>             \u003Ctr>               \u003Ctd>LCIS\u003C/td>               \u003Ctd>小叶内细胞轻度异常\u003C/td>               \u003Ctd>主要用于风险分层\u003C/td>               \u003Ctd>更多为长期随访，少数需手术\u003C/td>             \u003C/tr>           \u003C/tbody>         \u003C/table>       \u003C/div>       \u003Cblockquote class=\"material-breast-cancer-quote\">         🌱 \u003Cstrong>病例参考：\u003C/strong> 45岁女性体检发现乳腺结节，活检提示高分级DCIS，无症状。她因分级较高接受了局部切除与放疗。从中可以看出，分级决定了后续治疗路径。       \u003C/blockquote>       \u003Cdiv class=\"material-breast-cancer-tip material-breast-cancer-tip3\">         \u003Cspan>特别说明\u003C/span>         \u003Cul>           \u003Cli>LCIS和DCIS虽然都属于原位“癌变”，但处理原则不完全相同\u003C/li>         \u003C/ul>       \u003C/div>     \u003C/div>   \u003C/section>      \u003C!-- 04 不同分级与治疗选择 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg4\">     \u003Ch2 class=\"material-breast-cancer-h2\">       04 病理分级到底怎么影响治疗？选择方案一览     \u003C/h2>     \u003Cdiv class=\"material-breast-cancer-content\">       \u003Cp>         正如不同病情有不同对策，病理分级直接决定了治疗路线。ICIS分级相当于路口的红绿灯，指导医生做出快速决策。       \u003C/p>       \u003Cdiv class=\"material-breast-cancer-table-container\">         \u003Ctable class=\"material-breast-cancer-table3\" cellspacing=\"0\">           \u003Cthead>             \u003Ctr>               \u003Cth>分级\u003C/th>               \u003Cth>手术处理\u003C/th>               \u003Cth>放疗需求\u003C/th>               \u003Cth>药物治疗\u003C/th>             \u003C/tr>           \u003C/thead>           \u003Ctbody>             \u003Ctr>               \u003Ctd>低分级\u003C/td>               \u003Ctd>局部切除（保乳）为主\u003C/td>               \u003Ctd>部分患者可免除\u003C/td>               \u003Ctd>仅高危人群考虑内分泌治疗\u003C/td>             \u003C/tr>             \u003Ctr>               \u003Ctd>中分级\u003C/td>               \u003Ctd>局部切除+适当放疗\u003C/td>               \u003Ctd>大多建议配合\u003C/td>               \u003Ctd>有部分用药需求\u003C/td>             \u003C/tr>             \u003Ctr>               \u003Ctd>高分级\u003C/td>               \u003Ctd>范围扩大切除\u003C/td>               \u003Ctd>几乎都需接受放疗\u003C/td>               \u003Ctd>激素受体阳性可用内分泌药\u003C/td>             \u003C/tr>           \u003C/tbody>         \u003C/table>       \u003C/div>       \u003Cdiv class=\"material-breast-cancer-tip material-breast-cancer-tip4\">         \u003Cspan>⚡要知道\u003C/span>         \u003Cul>           \u003Cli>分级越高，干预越积极，目的是防止进展为浸润性癌\u003C/li>           \u003Cli>治疗选择需结合病理、影像和个人偏好共同决定\u003C/li>         \u003C/ul>       \u003C/div>       \u003Cblockquote class=\"material-breast-cancer-quote\">         \u003Cstrong>对比案例：\u003C/strong> 51岁男性DCIS中分级，仅切除病灶，半年后复查稳定。这说明病理分级辅助个体化诊治，不必“一刀切”。       \u003C/blockquote>     \u003C/div>   \u003C/section>      \u003C!-- 05 预后评估与随访监测 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg5\">     \u003Ch2 class=\"material-breast-cancer-h2\">       05 预后与监测：分级给健康管理划一条“警戒线”     \u003C/h2>     \u003Cdiv class=\"material-breast-cancer-content\">       \u003Cp>         很多人以为做完手术就是“结束”，其实对于DCIS来说，分级越高，今后复发甚至恶化为浸润性乳腺癌的风险越大。\u003Cbr>         \u003Cb>美国《新英格兰医学杂志》\u003C/b>一项随访10年的大型研究指出，高分级DCIS的复发率可达30%，而低分级不足10% \u003Cspan class=\"material-breast-cancer-ref\">（Wapnir et al., 2011）\u003C/span>。       \u003C/p>       \u003Cdiv class=\"material-breast-cancer-tip material-breast-cancer-tip5\">         \u003Cspan>📅 监测建议\u003C/span>         \u003Cul>           \u003Cli>第一次手术后2年内，每6月随访一次乳腺影像\u003C/li>           \u003Cli>低分级DCIS，可每年复查\u003C/li>           \u003Cli>高分级或复发风险高者，每半年复查比一年一次更合适\u003C/li>         \u003C/ul>       \u003C/div>       \u003Cblockquote class=\"material-breast-cancer-quote\">         \u003Cstrong>实际案例：\u003C/strong> 38岁女性，切除低分级DCIS后按照每年随访，五年未见复发。可以看出，规范监测有助于提前发现问题。       \u003C/blockquote>     \u003C/div>   \u003C/section>      \u003C!-- 06 致病机理与高危因素 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg6\">     \u003Ch2 class=\"material-breast-cancer-h2\">       06 为什么会得乳腺导管原位癌？高危因素解析     \u003C/h2>     \u003Cdiv class=\"material-breast-cancer-content\">       \u003Cul>         \u003Cli>           \u003Cstrong>年龄相关：\u003C/strong>DCIS发病以40-60岁女性为主，尤其是绝经前后，雌激素水平变化导致细胞分裂失调。         \u003C/li>         \u003Cli>           \u003Cstrong>遗传背景：\u003C/strong>家族中有乳腺癌（如母亲、姐妹）病例的人风险更高，相关基因（BRCA1/2）突变是已知危险信号。         \u003C/li>         \u003Cli>           \u003Cstrong>生活习惯：\u003C/strong>长期高脂饮食、缺乏运动、肥胖都可能增加乳腺细胞异常概率。         \u003C/li>         \u003Cli>           \u003Cstrong>高密度乳腺：\u003C/strong>影像学上乳腺致密者风险高于低密度乳腺者。         \u003C/li>         \u003Cli>           \u003Cstrong>激素药物：\u003C/strong>长期使用口服避孕药或激素替代治疗会提高某些人的风险。         \u003C/li>       \u003C/ul>       \u003Cp class=\"material-breast-cancer-ref-tip\">         研究表明，遗传因素和生活方式共同作用，但单一危险因素并不会决定发病，更多是多方面共同影响 \u003Cspan class=\"material-breast-cancer-ref\">(Anderson et al., 2014)\u003C/span>。       \u003C/p>     \u003C/div>   \u003C/section>      \u003C!-- 07 实用的预防措施与健康建议 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg7\">     \u003Ch2 class=\"material-breast-cancer-h2\">       07 日常哪些办法有帮助？简单实用的预防建议     \u003C/h2>     \u003Cdiv class=\"material-breast-cancer-content\">       \u003Cul>         \u003Cli>           \u003Cb>多吃深色蔬菜\u003C/b>：如西兰花、菠菜。\u003Cspan class=\"material-breast-cancer-highlight\">含有丰富抗氧化成分，有助于细胞修复，建议每餐至少有一份深色菜。\u003C/span>         \u003C/li>         \u003Cli>           \u003Cb>适量坚果补充\u003C/b>：如核桃和杏仁。富含不饱和脂肪酸和维生素E，对乳腺健康有益，每天少量即可。         \u003C/li>         \u003Cli>           \u003Cb>适度有氧运动\u003C/b>：如快走、游泳、骑行。每周保持3—5次，每次30分钟左右，有助于调节激素水平。         \u003C/li>         \u003Cli>           \u003Cb>规律作息\u003C/b>：保证每天充足睡眠，有益于内分泌平衡。         \u003C/li>         \u003Cli>           \u003Cb>定期体检\u003C/b>：建议30岁后每1-2年做乳腺影像检查，家族高危者可酌情提前和增加频率。         \u003C/li>       \u003C/ul>       \u003Cdiv class=\"material-breast-cancer-tip material-breast-cancer-tip6\">         \u003Cspan>☀️ 温和建议\u003C/span>         \u003Cul>           \u003Cli>任何饮食调节都要适合自己，保持均衡是关键\u003C/li>           \u003Cli>出现乳腺皮肤变化、持续肿块等，应及时到正规医院就诊\u003C/li>         \u003C/ul>       \u003C/div>     \u003C/div>   \u003C/section>    \u003C!-- 08 未来研究与新进展 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg8\">     \u003Ch2 class=\"material-breast-cancer-h2\">       08 未来趋势：医学研究在进展     \u003C/h2>     \u003Cdiv class=\"material-breast-cancer-content\">       \u003Cul>         \u003Cli>           新型分子分级：不仅关注细胞形态，还研究基因表达，精准评估进展和复发风险 \u003Cspan class=\"material-breast-cancer-ref\">(Schnitt et al., 2020)\u003C/span>。         \u003C/li>         \u003Cli>           个体化监测方案：未来会结合AI算法和大数据，不同分级、不同基因型患者将有更个性化随访计划。         \u003C/li>         \u003Cli>           更温和的治疗研究：对于部分低分级DCIS，尝试“非手术观察”策略，尽量减少过度治疗。         \u003C/li>       \u003C/ul>       \u003Cdiv class=\"material-breast-cancer-tip material-breast-cancer-tip7\">         \u003Cspan>未来可期🔬\u003C/span>         \u003Cul>           \u003Cli>定期关注新指南，和主治医生保持良好沟通，是更新健康观念的好方式\u003C/li>         \u003C/ul>       \u003C/div>       \u003Cblockquote class=\"material-breast-cancer-quote\">         \u003Cstrong>这一切的进步，其实都希望\u003C/strong>：帮助更多人安然地生活在进步的医学时代中。       \u003C/blockquote>     \u003C/div>   \u003C/section>    \u003C!-- 09 主要英文文献参考 -->   \u003Csection class=\"material-breast-cancer-section material-breast-cancer-bg9\">     \u003Ch2 class=\"material-breast-cancer-h2 material-breast-cancer-ref-title\">       09 参考资料     \u003C/h2>     \u003Cul class=\"material-breast-cancer-ref-list\">       \u003Cli>         Wapnir I.L., Dignam J.J., Fisher B., et al. (2011). Long-term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences after Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. \u003Ci>Journal of the National Cancer Institute, 103\u003C/i>(6):478-488.       \u003C/li>       \u003Cli>         Anderson W.F., PhD, Devesa S.S., et al. (2014). Epidemiology and Etiology of Breast Cancer: An Overview. \u003Ci>Breast Cancer Research, 16\u003C/i>(1): R7.       \u003C/li>       \u003Cli>         Schnitt S.J., Collins L.C. (2020). Biopsy Interpretation of the Breast, 3rd edition. \u003Ci>Lippincott Williams & Wilkins\u003C/i>.       \u003C/li>     \u003C/ul>   \u003C/section> \u003C/div>  \u003Cstyle> .material-breast-cancer-wrapper {   font-family: \"PingFang SC\", \"Microsoft Yahei\", Arial, sans-serif;   background: #fafbfc;   max-width: 770px;   margin: 0 auto;   color: #222;   line-height: 1.82;   padding: 30px 18px 46px 18px;   border-radius: 12px;   box-shadow: 0 4px 18px 0 rgba(106,125,146,0.07); } .material-breast-cancer-title {   font-size: 2.2em;   text-align: center;   margin-bottom: 23px;   font-weight: 800;   letter-spacing: 1.5px; } .material-breast-cancer-h2 {   font-size: 1.35em;   font-weight: 700;   margin-bottom: 10px;   margin-top: 30px;   border-left: 5px solid #68a2de;   padding-left: 12px;   letter-spacing: 1px; } .material-breast-cancer-section {   padding: 20px 14px 23px 14px;   border-radius: 10px;   margin-bottom: 25px;   box-sizing: border-box;   transition: background .24s; } .material-breast-cancer-bg1 { background: #e8f3fe;} .material-breast-cancer-bg2 { background: #f5faff;} .material-breast-cancer-bg3 { background: #fdf8ee;} .material-breast-cancer-bg4 { background: #f0faf4;} .material-breast-cancer-bg5 { background: #f9f1f4;} .material-breast-cancer-bg6 { background: #f8fded;} .material-breast-cancer-bg7 { background: #f2f8fd;} .material-breast-cancer-bg8 { background: #f5f5fc;} .material-breast-cancer-bg9 { background: #fafafa;} .material-breast-cancer-content { font-size: 1.05em; } .material-breast-cancer-data {   color: #3273dc;   font-weight: 600; } .material-breast-cancer-table-container {   overflow-x: auto;   margin: 14px 0 16px 0; } .material-breast-cancer-table, .material-breast-cancer-table2, .material-breast-cancer-table3 {   border-collapse: collapse;   width: 100%;   background: #fff;   border-radius: 8px;   box-shadow: 0 0 1px #ccc; } .material-breast-cancer-table th, .material-breast-cancer-table2 th, .material-breast-cancer-table3 th, .material-breast-cancer-table td, .material-breast-cancer-table2 td, .material-breast-cancer-table3 td {   font-size: 0.98em;   border: 1px solid #e1eaf1;   padding: 7px 8px;   text-align: center;   min-width: 70px; } .material-breast-cancer-table th, .material-breast-cancer-table2 th, .material-breast-cancer-table3 th {   background: #f2f9ff;   color: #4577ad;   font-weight: bold; } .material-breast-cancer-table td,  .material-breast-cancer-table2 td, .material-breast-cancer-table3 td {   color: #444;   background: #fdfdfd; } .material-breast-cancer-tip {   background: #eaf6e6;   border-left: 5px solid #7cc48f;   border-radius: 6px;   margin: 17px 0 7px 0;   padding: 13px 17px 10px 13px;   font-size: 0.98em; } .material-breast-cancer-tip span {   display: inline-block;   font-weight: 700;   color: #35793a;   margin-bottom: 3px; } .material-breast-cancer-tip ul {   margin: 0 0 0 15px;   padding: 0;   list-style: disc; } .material-breast-cancer-tip1 { background: #e8f2ff; border-color: #4c8ae1; } .material-breast-cancer-tip2 { background: #f5faff; border-color: #53acee; } .material-breast-cancer-tip3 { background: #f9e9c2; border-color: #ecb53a;} .material-breast-cancer-tip4 { background: #ebf5dd; border-color: #6dae41;} .material-breast-cancer-tip5 { background: #f9e8ef; border-color: #dc6b9c;} .material-breast-cancer-tip6 { background: #f1f8fd; border-color: #559acf;} .material-breast-cancer-tip7 { background: #f6f6fb; border-color: #736de2;} .material-breast-cancer-highlight {   color: #e0621e;   font-weight: bold;   background: #fff5e6;   border-radius: 3px;   padding: 1px 6px;   margin-left: 3px; } .material-breast-cancer-quote {   border-left: 5px solid #7ec8c9;   background: #f9fcfd;   border-radius: 6px;   color: #2a6666;   padding: 9px 14px 6px 12px;   margin: 19px 0 9px 0;   font-size: 1em; } .material-breast-cancer-ref {   color: #9962c3;   font-size: 0.96em;   margin-left: 6px; } .material-breast-cancer-ref-tip {   background: #f8f0fe;   padding: 8px 13px;   border-left: 4px solid #af7be4;   margin: 11px 0 0 0;   border-radius: 5px;   font-size: 0.96em; } .material-breast-cancer-ref-title {   border-left: 5px solid #9ea7d9; } .material-breast-cancer-ref-list {   margin: 15px 0 0 16px;   font-size: 0.99em; } .material-breast-cancer-ref-list li {   margin-bottom: 7px; } @media (max-width: 680px) {   .material-breast-cancer-title { font-size: 1.28em; }   .material-breast-cancer-wrapper { padding: 14px 4px 30px 5px; }   .material-breast-cancer-section { padding: 10px 2px 15px 5px; } } \u003C/style>","本文深入探讨乳腺导管原位癌（DCIS）的定义、病理分级的重要性及其对治疗选择的影响。同时介绍高危因素、监测建议和预防措施，为患者提供科学的健康管理建议。",542,"2025-07-31 09:20:29"," 乳腺导管原位癌的全面解析：病理分级与治疗选择指南  "," 乳腺导管原位癌, DCIS病理分级, 导管原位癌治疗, 乳腺癌早期诊断, 乳腺肿瘤治疗方案  "," 本文全面解析乳腺导管原位癌（DCIS）的病理分级标准与临床治疗选择，涵盖低中高级别DCIS特征、手术/放疗/内分泌治疗策略，帮助患者了解个性化治疗方案和预后管理。","2025-08-04 16:32:00",2,[33],{"menuId":34,"menuName":35,"parentId":20,"orderNum":31,"path":36,"component":37,"isFrame":38,"isCache":39,"menuType":40,"visible":41,"status":20,"createDept":6,"remark":17,"createTime":42,"children":43,"columnImage":44,"columnLogo":45,"uncheckedLogo":6,"checkedLogo":6,"isHot":41,"isHome":20,"forceLogin":20,"color":46,"seoTitle":47,"seoKeywords":48,"seoDescription":49,"contentNum":6,"promotionalPoster":50,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":51,"routerPath":36,"componentInfo":37},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":55,"success":53},{"pageNo":41,"pageSize":56,"result":57,"totalSize":20},10,[],{"code":9,"msg":10,"message":6,"data":59,"success":53},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]